Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Checkpoint and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLEC7A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLEC7A ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CLEC7A Products |
| Gene Delivery | CLEC7A Promise-ORF / Lentivirus Full-length ORF for stable cell lines and functional cell-based assays. |
View CLEC7A Products |
| Benchmark Ab | Anti-CLEC7A recombinant positive control / biosimilar. High-affinity binding validation. |
View CLEC7A Products |
| Validator | CLEC7A siRNA Set For knockdown verification in primary myeloid cells or cell lines. |
View CLEC7A Products |
| Related Target A | CLEC9A Myeloid C-type lectin receptor. Crucial for cross-screening to ensure specificity. |
View CLEC9A Products |
| Related Target B | CD206 (MRC1) M2 macrophage marker. Essential for validating macrophage polarization assays. |
View CD206 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity. |
| Subfamily counter screening (Off-target risk) | Homolog panel proteins (CLEC9A, CLEC4D, etc.) strictly verified by mass spectrometry and sequence analysis. |
| Lack of Controls | Clinical-grade benchmark antibodies (biosimilars) included as positive controls. |
| False Positives in Myeloid Screens | Sequence-verified siRNA included for specific knockdown validation. |
Live CLEC7A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLEC7A (Dectin-1) therapeutics is intensifying, with major players shifting focus from traditional mAbs to myeloid-targeting agonists and bispecific immune-engagers. As first-generation therapies reach the clinic, the next wave of R&D is targeting the reprogramming of immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonistic mAb | Innate Pharma, Academic Institutions | Solid Tumors, Hot Tumors | Receptor clustering assays (Need Lentivirus for high-expression stable cell lines) |
| Bispecific / Multispecific | Biotech Consortia | Refractory Cancers | Heterodimer validation (Need cross-reactive antigens & high-purity ECD-Fc) |
| Antagonistic mAb / Small Mol | Inflammatory/Autoimmune developers | Fungal Infections, Inflammatory Bowel Disease (IBD) | Selectivity assays against homologous C-type lectins (Need Mutant vs WT Proteins) |